Genmab A/S (GMAB) Competitors

$27.53 +0.49 (+1.80%)

Closing price 03:59 PM Eastern

Extended Trading

$27.53 +0.00 (+0.01%)

As of 04:10 PM Eastern

GMAB vs. TAK, ARGX, TEVA, ONC, and INSM

Should you be buying Genmab A/S stock or one of its competitors? The main competitors of Genmab A/S include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Insmed (INSM). These companies are all part of the "pharmaceutical products" industry.

How does Genmab A/S compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

: Genmab A/S has a net margin of 25.89% compared to Takeda Pharmaceutical's net margin of 2.58%. Genmab A/S's return on equity of 17.35% beat Takeda Pharmaceutical's return on equity.
Company Net Margins Return on Equity Return on Assets
Takeda Pharmaceutical 2.58% 10.60% 5.21%
Genmab A/S 25.89% 17.35% 11.69%
: Genmab A/S has a consensus target price of $39.07, suggesting a potential upside of 41.94%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts plainly believe Genmab A/S is more favorable than Takeda Pharmaceutical.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Takeda Pharmaceutical
0 Sell rating(s)
2 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
2.50
Genmab A/S
0 Sell rating(s)

3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
: Genmab A/S has lower revenue, but higher earnings than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Takeda Pharmaceutical $4.46T 0.01 $712.33M $0.24 68.93
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
: In the previous week, Genmab A/S had 8 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Genmab A/S and 6 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.75 beat Genmab A/S's score of 0.72 indicating that Takeda Pharmaceutical is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Takeda Pharmaceutical
4 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
: 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: Takeda Pharmaceutical has a beta of -0.06, suggesting that its stock price is 106% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	2.58%	10.60%	5.21%
Genmab A/S	25.89%	17.35%	11.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$4.46T	0.01	$712.33M	$0.24	68.93
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Takeda Pharmaceutical	4 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Takeda Pharmaceutical on 13 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to argenex?

argenex (NASDAQ:ARGX) and Genmab A/S (NASDAQ:GMAB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

: argenex has a net margin of 30.42% compared to Genmab A/S's net margin of 25.89%. argenex's return on equity of 38.51% beat Genmab A/S's return on equity.
Company Net Margins Return on Equity Return on Assets
argenex 30.42% 38.51% 32.59%
Genmab A/S 25.89% 17.35% 11.69%
: argenex currently has a consensus target price of $1,016.22, suggesting a potential upside of 27.87%. Genmab A/S has a consensus target price of $39.07, suggesting a potential upside of 41.94%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than argenex.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
argenex
0 Sell rating(s)
4 Hold rating(s)

18 Buy rating(s)

2 Strong Buy rating(s)
2.92
Genmab A/S
0 Sell rating(s)

3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
: argenex has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
argenex $4.15B 11.90 $1.29B $19.52 40.71
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
: In the previous week, Genmab A/S had 9 more articles in the media than argenex. MarketBeat recorded 14 mentions for Genmab A/S and 5 mentions for argenex. argenex's average media sentiment score of 0.72 beat Genmab A/S's score of 0.72 indicating that argenex is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
argenex
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
: 60.3% of argenex shares are held by institutional investors. Comparatively, 7.1% of Genmab A/S shares are held by institutional investors. 2.4% of argenex shares are held by insiders. Comparatively, 1.5% of Genmab A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
: argenex has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
argenex	30.42%	38.51%	32.59%
Genmab A/S	25.89%	17.35%	11.69%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.15B	11.90	$1.29B	$19.52	40.71
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats Genmab A/S on 12 of the 15 factors compared between the two stocks.

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Genmab A/S (NASDAQ:GMAB) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

: Genmab A/S presently has a consensus target price of $39.07, suggesting a potential upside of 41.94%. Teva Pharmaceutical Industries has a consensus target price of $41.56, suggesting a potential upside of 15.87%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts clearly believe Genmab A/S is more favorable than Teva Pharmaceutical Industries.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
Teva Pharmaceutical Industries
1 Sell rating(s)

0 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.80
: In the previous week, Teva Pharmaceutical Industries had 47 more articles in the media than Genmab A/S. MarketBeat recorded 61 mentions for Teva Pharmaceutical Industries and 14 mentions for Genmab A/S. Teva Pharmaceutical Industries' average media sentiment score of 0.82 beat Genmab A/S's score of 0.72 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
32 Very Positive mention(s)
6 Positive mention(s)
11 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
: 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 54.0% of Teva Pharmaceutical Industries shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Genmab A/S has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.
: Genmab A/S has a net margin of 25.89% compared to Teva Pharmaceutical Industries' net margin of 9.01%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Genmab A/S's return on equity.
Company Net Margins Return on Equity Return on Assets
Genmab A/S 25.89% 17.35% 11.69%
Teva Pharmaceutical Industries 9.01% 43.53% 8.19%
: Teva Pharmaceutical Industries has higher revenue and earnings than Genmab A/S. Genmab A/S is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
Teva Pharmaceutical Industries $17.35B 2.38 $1.41B $1.33 26.97

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	32 Very Positive mention(s)	6 Positive mention(s)	11 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	25.89%	17.35%	11.69%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76
Teva Pharmaceutical Industries	$17.35B	2.38	$1.41B	$1.33	26.97

Summary

Genmab A/S and Teva Pharmaceutical Industries tied by winning 8 of the 16 factors compared between the two stocks.

How does Genmab A/S compare to BeOne Medicines?

Genmab A/S (NASDAQ:GMAB) and BeOne Medicines (NASDAQ:ONC) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

: Genmab A/S presently has a consensus target price of $39.07, suggesting a potential upside of 41.94%. BeOne Medicines has a consensus target price of $390.58, suggesting a potential upside of 31.29%. Given Genmab A/S's stronger consensus rating and higher possible upside, analysts clearly believe Genmab A/S is more favorable than BeOne Medicines.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
BeOne Medicines
1 Sell rating(s)

2 Hold rating(s)

11 Buy rating(s)

0 Strong Buy rating(s)
2.71
: In the previous week, Genmab A/S had 10 more articles in the media than BeOne Medicines. MarketBeat recorded 14 mentions for Genmab A/S and 4 mentions for BeOne Medicines. BeOne Medicines' average media sentiment score of 1.28 beat Genmab A/S's score of 0.72 indicating that BeOne Medicines is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
BeOne Medicines
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
: 7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Genmab A/S has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.5, suggesting that its share price is 50% less volatile than the S&P 500.
: Genmab A/S has a net margin of 25.89% compared to BeOne Medicines' net margin of 5.37%. Genmab A/S's return on equity of 17.35% beat BeOne Medicines' return on equity.
Company Net Margins Return on Equity Return on Assets
Genmab A/S 25.89% 17.35% 11.69%
BeOne Medicines 5.37% 10.70% 6.03%
: Genmab A/S has higher earnings, but lower revenue than BeOne Medicines. Genmab A/S is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
BeOne Medicines $5.34B 6.11 $286.93M $2.52 118.05

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
BeOne Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	25.89%	17.35%	11.69%
BeOne Medicines	5.37%	10.70%	6.03%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76
BeOne Medicines	$5.34B	6.11	$286.93M	$2.52	118.05

Summary

Genmab A/S beats BeOne Medicines on 9 of the 17 factors compared between the two stocks.

How does Genmab A/S compare to Insmed?

Genmab A/S (NASDAQ:GMAB) and Insmed (NASDAQ:INSM) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

: Genmab A/S has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Genmab A/S $3.72B 4.61 $963M $1.55 17.76
Insmed $606.42M 49.63 -$1.28B -$6.41 N/A
: Genmab A/S has a net margin of 25.89% compared to Insmed's net margin of -210.54%. Genmab A/S's return on equity of 17.35% beat Insmed's return on equity.
Company Net Margins Return on Equity Return on Assets
Genmab A/S 25.89% 17.35% 11.69%
Insmed -210.54% -168.36% -57.33%
: 7.1% of Genmab A/S shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 2.1% of Insmed shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, Genmab A/S had 1 more articles in the media than Insmed. MarketBeat recorded 14 mentions for Genmab A/S and 13 mentions for Insmed. Insmed's average media sentiment score of 1.04 beat Genmab A/S's score of 0.72 indicating that Insmed is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Insmed
8 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Genmab A/S presently has a consensus target price of $39.07, suggesting a potential upside of 41.94%. Insmed has a consensus target price of $213.23, suggesting a potential upside of 52.92%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than Genmab A/S.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
3 Hold rating(s)

7 Buy rating(s)

2 Strong Buy rating(s)
2.92
Insmed
1 Sell rating(s)

0 Hold rating(s)

22 Buy rating(s)

2 Strong Buy rating(s)
3.00
: Genmab A/S has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Insmed has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	4.61	$963M	$1.55	17.76
Insmed	$606.42M	49.63	-$1.28B	-$6.41	N/A

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	25.89%	17.35%	11.69%
Insmed	-210.54%	-168.36%	-57.33%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	4 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Genmab A/S beats Insmed on 9 of the 16 factors compared between the two stocks.

Get Genmab A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMAB vs. The Competition

Export

Metric	Genmab A/S	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$17.16B	$3.39B	$6.25B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	17.76	38.92	29.03	28.47
Price / Sales	4.61	154.75	476.10	60.92
Price / Cash	16.43	57.88	27.62	36.52
Price / Book	3.02	7.03	9.67	6.67
Net Income	$963M	$23.62M	$3.55B	$332.53M
7 Day Performance	2.75%	3.78%	1.75%	2.03%
1 Month Performance	0.09%	7.30%	5.66%	9.23%
1 Year Performance	27.73%	67.15%	34.42%	39.62%

Genmab A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMAB Genmab A/S	4.7186 of 5 stars	$27.53 +1.8%	$39.07 +41.9%	N/A	$17.16B	$3.72B	17.76	3,029	Positive News Upcoming Earnings Analyst Revision
TAK Takeda Pharmaceutical	0.9919 of 5 stars	$16.36 -1.7%	N/A	N/A	$52.92B	$30.09B	68.15	47,455	News Coverage
ARGX argenex	3.9039 of 5 stars	$783.74 +0.4%	$1,016.22 +29.7%	N/A	$48.52B	$4.25B	40.15	1,863	Upcoming Earnings
TEVA Teva Pharmaceutical Industries	4.4816 of 5 stars	$31.31 +2.2%	$38.78 +23.9%	N/A	$35.23B	$17.26B	26.09	33,950	Trending News Earnings Report Analyst Downgrade Insider Trade
ONC BeOne Medicines	4.4234 of 5 stars	$298.90 -0.6%	$389.73 +30.4%	N/A	$33.00B	$5.34B	118.61	12,000	News Coverage Positive News Upcoming Earnings Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GMAB) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genmab A/S (GMAB) Competitors

GMAB vs. TAK, ARGX, TEVA, ONC, and INSM

How does Genmab A/S compare to Takeda Pharmaceutical?

Summary

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Summary

How does Genmab A/S compare to BeOne Medicines?

Summary

How does Genmab A/S compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genmab A/S (GMAB) Competitors

GMAB vs. TAK, ARGX, TEVA, ONC, and INSM

How does Genmab A/S compare to Takeda Pharmaceutical?

Summary

How does Genmab A/S compare to argenex?

Summary

How does Genmab A/S compare to Teva Pharmaceutical Industries?

Summary

How does Genmab A/S compare to BeOne Medicines?

Summary

How does Genmab A/S compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMAB vs. The Competition

Genmab A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools